Review anchor
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
CHEMBL4703
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform as ChEMBL target CHEMBL4703, mapped to UniProt P67775. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4703
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P67775
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform matters
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform is reviewed as Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (UniProt P67775); Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform shows clinical signal disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 24 compounds, and 19 assays, with lead potency reaching pChEMBL 9.6.
Protein context
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Sequence length is 309 aa.
Review this target as Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform, mapped to UniProt P67775. Sequence length is 309 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P67775
Protein
Disease context
glioblastoma multiforme
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform shows clinical signal disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include LB-100.
Start review with glioblastoma multiforme because it currently carries clinical signal support. Linked drugs include LB-100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 24 compounds, and 19 assays for this target. The dominant activity type is IC50. CHEMBL430266 is the current potency anchor at pChEMBL 9.6.
Use CHEMBL430266 as the tractability anchor when discussing potency (pChEMBL 9.6).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P67775, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why glioblastoma multiforme is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
24
Total Compounds
19
Total Assays
1
Approved Drugs
IC50: 17.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL430266
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL280487
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL17130
|
7.7 | IC50 | — |
|
|
No preferred name
CHEMBL1366322
|
7.2 | IC50 | — |
|
|
No preferred name
CHEMBL48449
|
6.8 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CANTHARIDIN
CHEMBL48449
|
2023 |
Source Header